CBG Producer Willow Biosciences Announces Record 43% Revenue Increase And Strategic Moves Ahead
CBG Producer Willow Biosciences Announces Record 43% Revenue Increase And Strategic Moves Ahead
CBG 製片人 Willow Biosciences 宣佈創紀錄的 43% 收入增長並推進戰略舉措
Willow Biosciences Inc., (OTC:CANSF) a frontrunner in biotech innovations for sustainable ingredient production, reported its financial and operational results Tuesday morning for the fourth quarter and fiscal year 2023.
可持續原料生產生物技術創新的領跑者Willow Biosciences Inc.（場外交易代碼：CANSF）週二上午公佈了第四季度和2023財年的財務和經營業績。
The year marked a period of significant reorganization and growth, culminating in a record revenue of $1.2 million, a 43% increase from the previous year.
這一年是重大重組和增長的時期，最終實現了創紀錄的120萬美元收入，比上年增長了43％。
In 2020, Willow announced a breakthrough in biotechnology, successfully developing a scalable process for producing cannabigerol (CBG) with over 99% purity and no detectable THC, which positions Willow to capture a significant market opportunity in high-purity cannabinoids.
2020年，Willow宣佈在生物技術方面取得突破，成功開發了一種可擴展的工藝，用於生產純度超過99％且沒有可檢測到的四氫大麻酚（CBG），這使Willow能夠在高純度大麻素方面抓住重大市場機會。
The company's innovation bore fruit with its corticosteroid manufacturing platform showing...
該公司的創新取得了成果，...
登入免費觀看全文
登入/註冊